Evaluating Neuroprotection in Aneurysm Coiling Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2011

Conditions
Stroke
Interventions
DRUG

NA-1

single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion

DRUG

Placebo

single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion

Trial Locations (14)

85013

Barrow Neurological Institute, Phoenix

94305

Stanford University Medical Center, Stanford

97239

Oregon Health and Science University, Portland

T2N 2T9

Foothills Medical Centre, Calgary

T6G 2B7

University of Alberta Hospital, Edmonton

B3H 3A7

QEII Health Sciences Centre - Halifax Infirmary, Halifax

L8X 2S2

Hamilton Health Sciences General Site, Hamilton

N6A 5A5

London Health Sciences Centre, London

K1Y 4E9

The Ottawa Hospital - Civic Campus, Ottawa

M5B 2W8

St. Michael's Hospital, Toronto

M5T 2S8

Toronto Western Hospital, Toronto

H2L 4M1

Hôpital Notre-Dame du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

G1J 1Z4

Hopital de l'Enfant Jesus, Québec

S7N0W8

Royal University Hospital, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Arbor Vita Corporation

INDUSTRY

lead

NoNO Inc.

INDUSTRY

NCT00728182 - Evaluating Neuroprotection in Aneurysm Coiling Therapy | Biotech Hunter | Biotech Hunter